The Motley Fool Previous Page

Why Omeros Shares Vaulted Higher

Sean Williams
September 19, 2013

Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.

What: Shares of Omeros (NASDAQ: OMER), a clinical-stage biopharmaceutical company focused on developing therapies to treat inflammation and central nervous system disorders, advanced as much as 11% today after announcing the initiation of a mid-stage trial for OMS824, the company's phosphodiesterase 10, or PDE10, inhibitor for the treatment of stable schizophrenia.

So what: To understand why shareholders are so excited today, we have to look back exactly a week ago to when Omeros reported positive early stage results from OMS824, pointing to the drug being w